These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19734404)

  • 1. Secondary hyperparathyroidism: pathophysiology and treatment.
    Saliba W; El-Haddad B
    J Am Board Fam Med; 2009; 22(5):574-81. PubMed ID: 19734404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies.
    Hudson JQ
    Ann Pharmacother; 2006 Sep; 40(9):1584-93. PubMed ID: 16912241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D treatment in chronic kidney disease.
    Andress DL
    Semin Dial; 2005; 18(4):315-21. PubMed ID: 16076355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of secondary hyperparathyroidism in dialysis patients].
    Di Luca M
    G Ital Nefrol; 2009; 26 Suppl 49():S36-48. PubMed ID: 19941277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The need for better control of secondary hyperparathyroidism.
    Locatelli F
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V15-19. PubMed ID: 15284355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology].
    Mazzaferro S; Cozzolino M; Marangella M; Strippoli GF; Messa P;
    G Ital Nefrol; 2007; 24 Suppl 37():S107-24. PubMed ID: 17347960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of hyperphosphatemia among patients with ESRD.
    Coladonato JA
    J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S107-14. PubMed ID: 16251245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M; Brancaccio D
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approaches to treatment of secondary hyperparathyroidism.
    Locatelli F; Limardo M; Pontoriero G
    Curr Opin Investig Drugs; 2008 Apr; 9(4):363-70. PubMed ID: 18393103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients.
    Monge M; Shahapuni I; Oprisiu R; El Esper N; Morinière P; Massy Z; Choukroun G; Fournier A
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):326-36. PubMed ID: 16932454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Contemporary opinions on the diagnosis and treatment of secondary hyperparathyroidism].
    Zawierucha J; Małyszko J; Małyszko J; Prystacki T; Marcinkowski W; Dryl-Rydzyńska T
    Przegl Lek; 2016; 73(7):497-503. PubMed ID: 29677420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D supplementation in CKD.
    Martin KJ; González EA
    Clin Nephrol; 2011 Apr; 75(4):286-93. PubMed ID: 21426882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ; Slatopolsky E
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapies for uremic secondary hyperparathyroidism.
    Torres PU; Prié D; Beck L; Friedlander G
    J Ren Nutr; 2006 Apr; 16(2):87-99. PubMed ID: 16567265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineral metabolism disturbances in patients with chronic kidney disease.
    Kestenbaum B; Belozeroff V
    Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease.
    Raggi P; Kleerekoper M
    Clin J Am Soc Nephrol; 2008 May; 3(3):836-43. PubMed ID: 18322050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiovascular calcification and accelerated atherosclerosis in chronic kidney disease].
    Cozzolino M; Butti A; Chiarelli G; Rocca-Rey L; Santagostino G; Gallieni M; Brancaccio D
    Ital Heart J Suppl; 2005 Jan; 6(1):25-8. PubMed ID: 15776728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D in kidney disease: pathophysiology and the utility of treatment.
    Qazi RA; Martin KJ
    Endocrinol Metab Clin North Am; 2010 Jun; 39(2):355-63, table of contents. PubMed ID: 20511057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
    Coyne D; Acharya M; Qiu P; Abboud H; Batlle D; Rosansky S; Fadem S; Levine B; Williams L; Andress DL; Sprague SM
    Am J Kidney Dis; 2006 Feb; 47(2):263-76. PubMed ID: 16431255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.